A detailed history of First Command Advisory Services, Inc. transactions in Vaxcyte, Inc. stock. As of the latest transaction made, First Command Advisory Services, Inc. holds 17 shares of PCVX stock, worth $609. This represents 0.0% of its overall portfolio holdings.

Number of Shares
17
Holding current value
$609
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 02, 2025

BUY
$37.76 - $92.13 $641 - $1,566
17 New
17 $0

Others Institutions Holding PCVX

About Vaxcyte, Inc.


  • Ticker PCVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,315,100
  • Market Cap $2.13B
  • Description
  • Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...
More about PCVX
Track This Portfolio

Track First Command Advisory Services, Inc. Portfolio

Follow First Command Advisory Services, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Command Advisory Services, Inc., based on Form 13F filings with the SEC.

News

Stay updated on First Command Advisory Services, Inc. with notifications on news.